Angiotensin-converting enzyme insertion/deletion polymorphism is a risk factor for thoracic aortic aneurysm in patients with bicuspid or tricuspid aortic valves

Journal of Thoracic and Cardiovascular Surgery

Volumn 144, Issue 2, 2012, Pages 390-395

  Foffa, Ilenia ^a,b   Murzi, Michele ^b,c   Mariani, Massimiliano ^c   Mazzone, Anna Maria ^c   Glauber, Mattia ^c   Ait Ali, Lamia ^a   Andreassi, Maria Grazia ^a,c  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b SCUOLA SUPERIORE SANT ANNA   (Italy)

^c G Monasterio Foundation CNR Regione Toscana   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; AGE; ALLELE; ANGIOCARDIOGRAPHY; AORTA; ARTICLE; BICUSPID AORTIC VALVE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; FEMALE; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; THORACIC AORTA ANEURYSM; TRICUSPID VALVE;

ADULT; AGED; AORTIC ANEURYSM, THORACIC; AORTIC VALVE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SEQUENCE DELETION;

EID: 84863984570     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2011.12.038     Document Type: Article

References (37)

1. E.M. Isselbacher Thoracic and abdominal aortic aneurysms Circulation 111 2005 816 828
2. M.J. Eagleton Molecular diagnoses and treatments - past, present, or future? Semin Vasc Surg 20 2007 128 134
3. I. El-Hamamsy, and M.H. Yacoub Cellular and molecular mechanisms of thoracic aortic aneurysms Nat Rev Cardiol 6 2009 771 786
4. H. Pannu, V. Tran-Fadulu, and D.M. Milewicz Genetic basis of thoracic aortic aneurysms and aortic dissections Am J Med Genet Semin 139 2005 10 16
5. K.A. Eagle Rationale and design of the national registry of genetically triggered thoracic aortic aneurysms and cardiovascular conditions (GenTAC) Am Heart J 157 2009 319 326
6. Y.M. Ruigrok, R. Elias, C. Wijmenga, and G.J. Rinkel A comparison of genetic chromosomal loci for intracranial, thoracic aortic, and abdominal aortic aneurysms in search of common genetic risk factors Cardiovasc Pathol 17 2008 40 47
7. H. Lu, D.L. Rateri, L.A. Cassis, and A. Daugherty The role of the renin-angiotensin system in aortic aneurysmal diseases Curr Hypertens Rep 10 2008 99 106
8. J.M.C. Yeung, M. Heeley, S. Gray, M.K. Lingam, G. Manning, and J.R. Nash Does the angiotensin-converting enzyme (ACE) gene polymorphism affect rate of abdominal aortic aneurysm expansion? Eur J Vasc Endovasc Surg 24 2002 69 71
9. C. Fatini, G. Pratesi, F. Sofi, F. Gensini, E. Sticchi, and B. Lari ACE DD genotype: a predisposing factor for abdominal aortic aneurysm Eur J Vasc Endovasc Surg 29 2005 227 232
10. L. Lucarini, E. Sticchi, F. Sofi, G. Pratesi, C. Pratesi, and R. Pulli ACE and TGFBR1 genes interact in influencing the susceptibility to abdominal aortic aneurysm Atherosclerosis 202 2009 205 210
11. A. Daugherty, M.W. Manning, and L.A. Cassis Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice J Clin Invest 105 2000 1605 1612
12. L.A. Cassis, M. Gupte, S. Thayer, X. Zhang, R. Charnigo, and D.A. Howatt ANG II infusion promotes abdominal aortic aneurysms independent of increased blood pressure in hypercholesterolemic mice Am J Physiol Heart Circ Physiol 296 2009 H1660 H1665
13. J.P. Habashi, D.P. Judge, T.M. Holm, R.D. Cohn, B.L. Loeys, and T.K. Cooper Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome Science 312 2006 117 121
14. K. Tsunemi, S. Takai, M. Nishimoto, A. Yuda, S. Hasegawa, and Y. Sawada Possible roles of angiotensin II-forming enzymes, angiotensin converting enzyme and chymase-like enzyme, in the human aneurysmal aorta Hypertens Res 25 2002 817 822
15. M.J. Eagleton, N. Ballard, E. Lynch, S.D. Srivastava, G.R. Upchurch Jr., and J.C. Stanley Early increased MT1-MMP expression and late MMP-2 and MMP-9 activity during angiotensin II induced aneurysm formation J Surg Res 135 2006 345 351
16. K.J. Gordon, and G.C. Blobe Role of transforming growth factor-β superfamily signaling pathways in human disease Biochim Biophys Acta 1782 2008 197 228
17. B. Loeys, and A. De Paepe New insights in the pathogenesis of aortic aneurysms Verh K Acad Geneeskd Belg 70 2008 69 84
18. S. Heeneman, J.C. Sluimer, and M.J. Daemen Angiotensin-converting enzyme and vascular remodeling Circ Res 101 2007 441 454
19. M. Nishimoto, S. Takai, H. Fukumoto, K. Tsunemi, A. Yuda, and Y. Sawada Increased local angiotensin II formation in aneurysmal aorta Life Sci 71 2002 2195 2205
20. B. Rigat, C. Hubert, F. Alhenc-Gelas, F. Cambien, P. Corvol, and F. Soubrier An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels J Clin Invest 86 1990 1343 1346
21. A.H. Danser, M.A. Schalekamp, W.A. Bax, A.M. van den Brink, P.R. Saxena, and G.A. Riegger Angiotensin-converting enzyme in the human heart: effect of the deletion/insertion polymorphism Circulation 92 1995 1387 1388
22. G.T. Jones, A.R. Thompson, F.M. van Bockxmeer, H. Hafez, J.A. Cooper, and J. Golledge Angiotensin II type 1 receptor 1166C polymorphism is associated with abdominal aortic aneurysm in three independent cohorts Arterioscler Thromb Vasc Biol 28 2008 764 770
23. R.O. Bonow, B.A. Carabello, K. Chatterjee, A.C. de Leon Jr., D.P. Faxon, and M.D. Freed 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons J Am Coll Cardiol 52 2008 e1 e142
24. D.M. Milewicz, E.S. Regalado, and D.C. Guo Treatment guidelines for thoracic aortic aneurysms and dissections based on the underlying causative gene J Thorac Cardiovasc Surg 140 2010 S2 S4
25. T.M. Sundt III Replacement of the ascending aorta in bicuspid aortic valve disease: where do we draw the line? J Thorac Cardiovasc Surg 140 2010 S41 S44
26. M.J. RoOsborne-Pellegrin, M. Coutard, P. Poitevin, J.B. Michel, and B.I. Levy Induction of aneurysms in the rat by a stenosing cotton ligature around the inter-renal aorta Int J Exp Pathol 75 1994 179 190
27. S. Liao, M. Miralles, B.J. Kelley, J.A. Curci, M. Borhani, and R.W. Thompson Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors J Vasc Surg 33 2001 1057 1064
28. H. Nagashima, K. Uto, Y. Sakomura, Y. Aoka, A. Sakuta, and S. Aomi An angiotensin-converting enzyme inhibitor, perindopril, but not carvedilol prevents against beta-aminopropionitril monofumarate-induced aortic dissection in rat model J Vasc Surg 36 2002 818 823
29. J.P. Habashi, J.J. Doyle, T.M. Holm, H. Aziz, F. Schoenhoff, and D. Bedja Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism Science 332 2011 361 365
30. D.G. Hackam, D. Thiruchelvam, and D.A. Redelmeier Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study Lancet 368 2006 659 666
31. A.T. Yetman, R.A. Bornemeier, and B.W. McCrindle Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome Am J Cardiol 95 2005 1125 1127
32. A.A. Ahimastos, A. Aggarwal, K.M. D'Orsa, M.F. Formosa, A.J. White, and R. Savarirayan Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial JAMA 298 2007 1539 1547
33. B.S. Brooke, J.P. Habashi, D.P. Judge, N. Patel, B. Loeys, and H.C. Dietz III Angiotensin II blockade and aortic-root dilation in Marfan's syndrome N Engl J Med 358 2008 2787 2795
34. R.V. Lacro, H.C. Dietz, L.M. Wruck, T.J. Bradley, S.D. Colan, and R.B. Devereux Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome Am Heart J 154 2007 624 631
35. T. Radonic, P. de Witte, M.J. Baars, A.H. Zwinderman, B.J. Mulder, M. Groenink COMPARE Study Group Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial Trials 11 2010 3
36. D. Detaint, P. Aegerter, F. Tubach, I. Hoffman, H. Plauchu, and Y. Dulac Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome Arch Cardiovasc Dis 103 2010 317 325
37. X. Jeunemaitre Genetics of the human renin angiotensin system J Mol Med 86 2008 637 641